Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 in Myeloid Malignancies.

Cells - 8 Jul 2020

Rinke Jenny, Chase Andrew, Cross Nicholas C P, Hochhaus Andreas, Ernst Thomas

Abstract excerpt

Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silencing through trimethylation of H3K27. EZH2 dysregulation is highly tumorigenic and has been observed in various...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Enhancer of Zeste Homolog 2 Protein
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Polycomb Repressive Complex 2

Share to Repressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 32650416
DOI: 10.3390/cells9071639
PMCID: PMC7407223

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 in Myeloid Malignancies.PMID 32650416Read ↗

The epigenetic role of EZH2 in acute myeloid leukemiaSemantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

Targeting EZH2 in cancer.Semantic proximity Read ↗

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent mannerSemantic proximity Read ↗

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.Semantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.Semantic proximity Read ↗

Aberrations of EZH2 in cancer.Semantic proximity Read ↗

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.Semantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsSemantic proximity Read ↗

Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.